---
title: "Jincheng Pharm: Mirabegron has obtained approval for the listing application of chemical raw materials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258476902.md"
description: "According to the Zhitong Finance APP, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. recently received the \"Approval Notice for the Listing Application of Chemical Raw Materials\" issued by the National Medical Products Administration. The name of the chemical raw material is: Mirabegron. Mirabegron is a selective β-3 adrenergic receptor agonist, primarily used for the treatment of overactive bladder (OAB), including symptoms such as urinary incontinence, urgency, and frequency"
datetime: "2025-09-23T08:19:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258476902.md)
  - [en](https://longbridge.com/en/news/258476902.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258476902.md)
---

# Jincheng Pharm: Mirabegron has obtained approval for the listing application of chemical raw materials

According to the Zhitong Finance APP, Jincheng Pharm (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration. The name of the chemical raw material is: Mirabegron. Mirabegron is a selective β-3 adrenergic receptor agonist, primarily used for the treatment of overactive bladder (OAB), including symptoms such as urinary incontinence, urgency, and frequency

### Related Stocks

- [300233.CN](https://longbridge.com/en/quote/300233.CN.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [20:38 ETHyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"](https://longbridge.com/en/news/287135394.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [Zunder launches charging infrastructure software Kawat for third parties](https://longbridge.com/en/news/287080731.md)